Pluvicto (Lu-177 Vipivotide Tetraxetan)
FDA-approved PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer. Mays Cancer Center is the only civilian center in South Texas offering Pluvicto.
Approved
FDA Status
Lu-177
Radioligand Therapy
PSMA
Target
Only Civilian
Center in South TX
Executive Summary
Strategic overview for Pluvicto
- Only FDA-approved radioligand therapy for prostate cancer
- Strong Phase 3 data (VISION + PSMAfore) with OS and rPFS benefits
- Mays Cancer Center is the only civilian academic center offering Pluvicto in South Texas
- PSMA PET/CT companion diagnostic enables biomarker-driven patient selection
- Novartis commercial infrastructure and patient access programs
- Theranostics expertise positions Mays for next-generation RLT
- Persistent 177Lu supply constraints could send patients to competitors
- 225Ac-PSMA and next-gen RLTs may displace Pluvicto
- Military treatment facilities (BAMC) could start offering Pluvicto
- Reimbursement policy changes could reduce margins
- Novartis could redirect supply to higher-volume centers
- Regulatory changes to NRC licensing could increase compliance burden
Molecule Profile
FDA-approved radioligand therapy for metastatic castration-resistant prostate cancer. Mays Cancer Center is the only civilian academic center in South Texas offering Pluvicto, serving a critical unmet need in the region.
Pluvicto (177Lu-PSMA-617)
(lutetium Lu 177 vipivotide tetraxetan)PluvictoApprovedModality
RLT
Target
PSMA
Mechanism
Radioligand therapy (RLT) using lutetium-177 conjugated to PSMA-targeting small molecule. Delivers targeted beta radiation to PSMA-expressing prostate cancer cells, causing DNA double-strand breaks and tumor cell death.
Route
/portfolio/pluvicto
Key Metric
$1.5B+ Revenue (2025)
Sponsor
Novartis
Indications
Regulatory Designations
Mechanism of Action
Targeting PSMA (Prostate-Specific Membrane Antigen)
PSMA-617 ligand binds to PSMA on the surface of prostate cancer cells with high affinity. The conjugate is internalized via receptor-mediated endocytosis. Lutetium-177 emits beta radiation causing DNA double-strand breaks in the target cell and nearby cells within the ~2mm radiation range (crossfire effect). This results in cell cycle arrest and apoptosis of PSMA-expressing tumor cells.
Radioisotope
Lutetium-177 (177Lu)
Ligand
PSMA-617 — high-affinity small molecule PSMA inhibitor (Glu-urea-Lys motif)
Linker
DOTA chelator conjugating 177Lu to PSMA-617 ligand
Half-life
6.7 days (physical half-life of 177Lu)
Dosimetry
Fixed dose of 7.4 GBq (200 mCi) per cycle, administered IV over 30 minutes. Up to 6 cycles given Q6W. Radiation dose to kidneys and bone marrow monitored but dosimetry-guided dosing not standard of care.
Key Advantages
- Beta radiation: Beta particles (β⁻) with maximum energy 0.497 MeV, tissue penetration ~2mm
- Crossfire effect: Beta particles from 177Lu travel ~2mm in tissue, killing neighboring PSMA-negative tumor cells within the radiation range. This partially addresses tumor heterogeneity in PSMA expression.
- Imaging companion: Requires PSMA PET/CT scan (68Ga-PSMA-11 or 18F-DCFPyL) prior to treatment to confirm PSMA expression. At least one PSMA-positive metastatic lesion required; no PSMA-negative dominant lesions allowed (VISION criteria).
Clinical Evidence
Active and completed clinical trials
| NCT Number | Title | Phase | Status | Indication | Enrollment |
|---|---|---|---|---|---|
| NCT03511664 | VISION: A Phase 3, Randomized, Open-Label Study of 177Lu-PSMA-617 in mCRPC Previously Treated With ARPI and Taxane Chemotherapy | Phase 3 | Completed | mCRPC (post-ARPI, post-taxane) | 831/831 |
| NCT04689828 | PSMAfore: A Phase 3 Study of 177Lu-PSMA-617 vs Change of ARPI in PSMA-Positive mCRPC | Phase 3 | Completed | mCRPC (post-ARPI, pre-chemotherapy) | 468/468 |
Efficacy Results
Overall Survival (VISION)
15.3 months
vs. 11.3 months (control)
Radiographic PFS (VISION)
8.7 months
vs. 3.4 months (control)
PSA Response ≥50% (VISION)
46%
vs. 7.1% (control)
rPFS (PSMAfore)
12.0 months
vs. 5.6 months (change of ARPI)
OS (PSMAfore, updated)
Positive trend (HR 0.84)
vs. Confounded by 84% crossover from ARPI arm to Pluvicto
ORR (PSMAfore)
51%
vs. 14.5% (change of ARPI)
Safety Profile
Adverse event summary for Pluvicto
| Adverse Event | All Grades | Grade 3+ | Manageable |
|---|---|---|---|
| Dry mouth | 39% | 0% | Yes |
| Nausea | 35% | 2% | Yes |
| Fatigue | 43% | 5% | Yes |
| Thrombocytopenia | 17% | 8% | Yes |
| Anemia | 32% | 13% | Yes |
| Lymphopenia | 24% | 8% | Yes |
| Bone pain | 18% | 3% | Yes |
Regulatory Timeline
Regulatory milestones for Pluvicto
FDA Approval (VISION — post-ARPI, post-taxane mCRPC)
2022-03
EMA Approval
2022-12
REMS Program Implementation
2022-03
FDA Label Expansion (PSMAfore — pre-chemo mCRPC)
2025-01
PSMAddition Phase 3 Data Readout
2026-Q4
Potential mHSPC Approval (PSMAddition)
2027-Q4
FDA Approval (VISION — post-ARPI, post-taxane mCRPC)
2022-03
FDA approved Pluvicto for PSMA-positive mCRPC in patients previously treated with ARPI and taxane-based chemotherapy. Approved alongside Locametz (68Ga-PSMA-11) as companion diagnostic.
EMA Approval
2022-12
European Medicines Agency granted marketing authorization for Pluvicto in the same indication as FDA approval.
REMS Program Implementation
2022-03
FDA-required Risk Evaluation and Mitigation Strategy (REMS) ensures Pluvicto is administered only at certified healthcare facilities with radiation safety infrastructure and trained personnel.
FDA Label Expansion (PSMAfore — pre-chemo mCRPC)
2025-01
sNDA approved based on PSMAfore data, expanding Pluvicto label to mCRPC patients who progressed on one prior ARPI, regardless of prior chemotherapy. Doubles addressable patient population.
PSMAddition Phase 3 Data Readout
2026-Q4
Primary analysis of PSMAddition trial in mHSPC expected. If positive, would support sNDA for first-line metastatic prostate cancer.
Potential mHSPC Approval (PSMAddition)
2027-Q4
If PSMAddition is positive, sNDA filing for mHSPC indication would represent the largest patient population expansion for Pluvicto.
Coverage Intelligence
Medicare and payer coverage status for Pluvicto
J-Code: J9399 (unclassified antineoplastic) transitioning to J9055
Medicare covers Pluvicto for FDA-approved indications under Part B as a physician-administered drug. Reimbursement via hospital outpatient or freestanding nuclear medicine facility. ASP-based reimbursement with buy-and-bill model.
J-Code: J9055
Covers Pluvicto for PSMA-positive mCRPC per FDA labeling. Requires prior PSMA PET/CT demonstrating PSMA-positive disease. Documentation of prior ARPI therapy (and prior taxane for VISION indication) required.
J-Code: J9055
Covers Pluvicto for FDA-approved indications. Requires PSMA PET/CT within 90 days of treatment initiation. Site must be Pluvicto REMS-certified. Up to 6 cycles covered.
nuclear Pharmacy
Pluvicto is supplied as a ready-to-use radiopharmaceutical from Novartis-contracted nuclear pharmacies. Each dose (7.4 GBq / 200 mCi 177Lu) is calibrated for the scheduled administration time.
dose Timing
30-minute IV infusion
rems
Pluvicto REMS
facility Requirements
Dedicated nuclear medicine treatment room with appropriate shielding; Lead-lined waste storage for radioactive materials; Radiation monitoring equipment (Geiger counter, wipe test supplies); Emergency spill kit for radioactive material; Patient restroom designated for radioactive waste during treatment day; IV infusion equipment compatible with radioactive administration sets; Personnel dosimetry (TLD badges) for all staff; Written radiation safety procedures and emergency protocols
mays Cancer Center Capacity
4–6 patients per week
Market Opportunity
Radioligand therapy market segments
Radioligand Therapy (global)
$4B
Growth: 25% CAGR
Share: Pluvicto is market leader (~85% of RLT market in prostate cancer)
mCRPC (post-ARPI, post-taxane — VISION)
$2.5B
Growth: 12% CAGR
Share: ~35% market share in eligible population
mCRPC (post-ARPI, pre-chemo — PSMAfore)
$3.5B
Growth: 18% CAGR
Share: ~20% market share (growing rapidly post-label expansion)
mHSPC (potential — PSMAddition)
$8B
Growth: 10% CAGR
Share: Target 10% if PSMAddition positive (future)
Competitive Landscape
Competitors in the mCRPC / radioligand therapy space
Multiple (academic / Novartis)
Alpha-emitting radioligand with higher linear energy transfer (LET) than 177Lu beta particles. Potential for greater tumor cell kill per decay, especially in Pluvicto-resistant disease.
Pfizer (enza) / J&J (abi)
Oral AR pathway inhibitors that are standard of care in mCRPC. Pluvicto is positioned after ARPI failure (VISION) or as alternative to ARPI switch (PSMAfore).
Sanofi
Taxane chemotherapy approved for mCRPC after docetaxel. Competes with Pluvicto in post-ARPI, post-docetaxel setting.
Multiple (Ambrx/J&J, others)
Antibody-drug conjugates targeting PSMA with cytotoxic payloads instead of radiation. Could offer PSMA-targeted therapy without nuclear medicine infrastructure.
Financial Analysis
Reimbursement and coverage economics for Pluvicto
J-Code
J9055 (lutetium Lu 177 vipivotide tetraxetan)
Transitional: J9399 (unclassified, used prior to permanent J-code assignment)
Cost per Dose
$42,500 (approximate WAC per 7.4 GBq dose)
Full course: $255,000 (6 cycles)
Payer Mix
Medicare: 65% of patients (mCRPC age demographics)
Commercial: 25%
VA: 8%
Prior Authorization
Most commercial payers require PA. Key requirements: PSMA PET/CT confirming PSMA positivity, documentation of prior ARPI failure, pathology confirming prostate adenocarcinoma, ECOG PS 0-2.
KOL Simulation
Simulated nuclear medicine and urology KOL responses
KOL Personas
Nuclear Medicine Physician / Authorized User
Mays Cancer Center
Medical Oncologist — GU Oncology
Academic Medical Center
Scenarios
PSMAfore Label Expansion Doubles Eligible Patient Population
OpportunityFDA approves expanded Pluvicto label based on PSMAfore, allowing use in mCRPC after one prior ARPI without requiring prior taxane chemotherapy. This doubles the addressable patient population and creates significant demand increase.
Pluvicto Supply Constraints Limit Patient Access
HighNovartis reports continued supply constraints for Pluvicto due to 177Lu isotope manufacturing capacity limitations. Wait times at major centers reach 6–8 weeks. Mays Cancer Center must optimize scheduling to serve South Texas patient demand.
Nuclear Medicine Physician / Authorized User
Welcomes the expanded indication but concerned about capacity to meet increased demandPSMAfore gives us the data to use Pluvicto earlier, which is great for patients. But we need to be realistic about capacity — we're the only civilian center offering this in South Texas. We need to invest in additional treatment slots and potentially a second nuclear medicine suite.
Medical Oncologist — GU Oncology
Enthusiastic about earlier Pluvicto use and eager to update treatment sequencing algorithmsThe PSMAfore data changes how I think about mCRPC sequencing. Many of my patients dread chemotherapy — now I can offer them a targeted therapy with a 51% response rate after their first ARPI. The key challenge is getting them treated without a 2-month wait.
Nuclear Medicine Physician / Authorized User
Deeply concerned about supply limitations impacting patient outcomesSupply constraints for a life-saving therapy are unacceptable. We have patients with progressing mCRPC who've been told they need to wait 6–8 weeks. We need Novartis to prioritize centers like ours that serve underserved populations with no alternative access point.
Risk Assessment
Key operational and clinical risks for the Pluvicto program
177Lu Isotope Supply Constraints
criticalGlobal demand for Pluvicto exceeds 177Lu production capacity. Supply constraints create 6–8 week wait times at many centers, potentially causing disease progression while patients wait for treatment.
Mitigation: Maintain strong Novartis relationship for priority allocation. Optimize scheduling efficiency to maximize treatment slots. Advocate for regional supply hub. Monitor Novartis capacity expansion investments.
Nuclear Medicine Infrastructure Capacity Limits
highSingle nuclear medicine suite and limited authorized users constrain Mays Cancer Center's ability to serve growing patient demand, especially after PSMAfore label expansion.
Mitigation: Invest in second nuclear medicine treatment suite. Recruit additional authorized users. Implement efficient scheduling with minimal idle time. Consider weekend treatment slots.
Reimbursement Complexity and Prior Authorization Delays
mediumComplex reimbursement landscape with buy-and-bill model, varying J-codes, and payer-specific prior authorization requirements can delay treatment initiation. Institutional financial risk with $42,500/dose buy-and-bill.
Mitigation: Dedicated financial coordinator for Pluvicto patients. Pre-verify insurance before ordering dose. Novartis patient access programs for uninsured/underinsured. Maintain expertise in Medicare Part B billing.
225Ac-PSMA and Next-Gen RLT Competition
mediumAlpha-emitting 225Ac-PSMA-617 and other next-generation radioligand therapies are in development and may offer superior efficacy, particularly in Pluvicto-resistant patients. Could eventually displace Pluvicto.
Mitigation: Position Mays Cancer Center for next-gen RLT trials. Maintain relationships with Novartis and other RLT developers. Build theranostics expertise that is modality-agnostic.
Cumulative Hematologic and Renal Toxicity
mediumRepeated 177Lu dosing causes cumulative bone marrow suppression and potential renal toxicity. Grade 3+ cytopenias may require dose delays or treatment discontinuation, reducing clinical benefit.
Mitigation: Rigorous lab monitoring before each cycle. Proactive dose modifications per protocol. Renal function monitoring with early intervention. Patient education on hydration and bone marrow support.
Lifecycle Position
Pluvicto in the commercial phase of the pharma lifecycle
Strategic Recommendations
SWOT analysis and strategic priorities for Pluvicto at Mays
- + Only FDA-approved radioligand therapy for prostate cancer
- + Strong Phase 3 data (VISION + PSMAfore) with OS and rPFS benefits
- + Mays Cancer Center is the only civilian academic center offering Pluvicto in South Texas
- + PSMA PET/CT companion diagnostic enables biomarker-driven patient selection
- + Novartis commercial infrastructure and patient access programs
- + Theranostics expertise positions Mays for next-generation RLT
- - 177Lu supply constraints limit patient throughput
- - Requires specialized nuclear medicine infrastructure (REMS-certified facility)
- - Complex buy-and-bill reimbursement model with financial risk
- - Limited authorized users and treatment suite capacity
- - 6-week treatment cycle creates long total treatment duration (36 weeks for 6 cycles)
- - Cannot be administered at standard infusion centers
- * PSMAfore label expansion doubles addressable mCRPC population
- * PSMAddition could expand to mHSPC — dramatically larger market
- * Regional monopoly as only civilian Pluvicto center in South Texas
- * Growing theranostics field attracts talent and research funding
- * Combination strategies with ARPIs, PARP inhibitors, immunotherapy
- * Second nuclear medicine suite and additional authorized users
- ! Persistent 177Lu supply constraints could send patients to competitors
- ! 225Ac-PSMA and next-gen RLTs may displace Pluvicto
- ! Military treatment facilities (BAMC) could start offering Pluvicto
- ! Reimbursement policy changes could reduce margins
- ! Novartis could redirect supply to higher-volume centers
- ! Regulatory changes to NRC licensing could increase compliance burden
Publication Tracker
Key publications for Pluvicto and PSMA-targeted therapies
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION)
Sartor O, de Bono J, Chi KN et al.
DOI: 10.1056/NEJMoa2107322
TheraP: a randomised phase 2 trial of 177Lu-PSMA-617 vs cabazitaxel in mCRPC
Hofman MS, Emmett L, Sandhu S et al.
DOI: 10.1016/S0140-6736(21)00237-8
PSMAfore: 177Lu-PSMA-617 vs androgen receptor pathway inhibitor change of therapy
Fizazi K, Herrmann K, Krause BJ et al.
DOI: 10.1016/S0140-6736(24)00055-2
PSMA PET and PET/CT for diagnostic and therapeutic decision-making in prostate cancer
Emmett L, Willowson K, Violet J et al.
DOI: 10.2967/jnumed.119.227462